Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment of progressive systemic sclerosis using factor XIII.

L Guillevin, B Chouvet, C Mery

    Pharmatherapeutica
    |January 1, 1985
    PubMed
    Summary

    Factor XIII treatment significantly improved skin symptoms and motor function in progressive systemic sclerosis patients compared to placebo. The treatment demonstrated good tolerability with no adverse effects reported during the trial.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Changes in the gut microbiota of pseudoxanthoma elasticum patients.

    Annales de dermatologie et de venereologie·2024
    Same author

    [Malignant transformation of an eccrine spiradenoma].

    Annales de dermatologie et de venereologie·2017
    Same author

    Evaluation of natural zeolite as microorganism support medium in nitrifying batch reactors: influence of zeolite particle size.

    Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering·2012
    Same author

    Circumscribed palmo-plantar hypokeratosis: a disease of desquamation? Immunohistological study of five cases and literature review.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2010
    Same author

    [Ascitis associated with ischemic bowel revealing systemic lupus].

    Gastroenterologie clinique et biologique·2010
    Same author

    Subcutaneous dermatofibrosarcoma protuberans masquerading as a cyst.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2007

    Area of Science:

    • Rheumatology
    • Dermatology
    • Hematology

    Background:

    • Progressive systemic sclerosis (PSS) is a debilitating autoimmune disease characterized by skin thickening and organ fibrosis.
    • Current treatments for PSS have limited efficacy in addressing its diverse manifestations.
    • Factor XIII, a key enzyme in the coagulation cascade, has potential therapeutic roles beyond hemostasis.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of Factor XIII in patients with progressive systemic sclerosis.
    • To compare Factor XIII treatment against a placebo in a randomized controlled setting.

    Main Methods:

    • A double-blind, randomized crossover trial involving 25 patients with PSS.
    • Patients received intravenous Factor XIII or placebo for 3 weeks, followed by a 6-week washout period and crossover to the alternative treatment.

    Related Experiment Videos

  • Physician and patient assessments, along with a functional index for motor disability, were used for evaluation.

    • Main Results:

    • Factor XIII significantly improved cutaneous manifestations of PSS compared to placebo.
    • Patient- and physician-reported outcomes indicated superior efficacy of Factor XIII.
    • A significant improvement in the motor function index was observed with Factor XIII treatment.
    • Factor XIII exhibited good local and general tolerability, with no adverse events reported.

    Conclusions:

    • Factor XIII is an effective and well-tolerated treatment for the cutaneous and motor disability symptoms of progressive systemic sclerosis.
    • Further research into Factor XIII's role in autoimmune fibrotic diseases is warranted.